DK2054082T3 - Anvendelse af D114-antagonister til behandling af iskæmiske skader eller vaskulær insufficiens - Google Patents

Anvendelse af D114-antagonister til behandling af iskæmiske skader eller vaskulær insufficiens

Info

Publication number: DK2054082T3
Authority: DK; Denmark
Prior art keywords: antagonists; ischemic injury; vascular insufficiency; treat ischemic; treat
Prior art date: 2006-08-07

Application number

DK07811137.4T

Other languages

English (en)

Inventor

Stanley J Wiegand

Nicholas J Papadopoulos

Ivan B Lobov

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-07

Filing date

2007-08-07

Publication date

2013-01-21

2007-08-07 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2013-01-21 Application granted granted Critical

2013-01-21 Publication of DK2054082T3 publication Critical patent/DK2054082T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Marine Sciences & Fisheries (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DK07811137.4T 2006-08-07 2007-08-07 Anvendelse af D114-antagonister til behandling af iskæmiske skader eller vaskulær insufficiens DK2054082T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US83600306P	2006-08-07	2006-08-07
PCT/US2007/017546 WO2008019144A2 (en)	2006-08-07	2007-08-07	Threapeutic methods for treating vascular eye disorders with dll4 antagonists

Publications (1)

Publication Number	Publication Date
DK2054082T3 true DK2054082T3 (da)	2013-01-21

Family

ID=38904599

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07811137.4T DK2054082T3 (da)	2006-08-07	2007-08-07	Anvendelse af D114-antagonister til behandling af iskæmiske skader eller vaskulær insufficiens

Country Status (33)

Country	Link
US (1)	US20080181893A1 (da)
EP (1)	EP2054082B1 (da)
JP (1)	JP5529536B2 (da)
KR (1)	KR101497355B1 (da)
CN (1)	CN101500605B (da)
AU (1)	AU2007281916B2 (da)
BR (1)	BRPI0716424B8 (da)
CA (1)	CA2660235C (da)
CO (1)	CO6150190A2 (da)
CR (1)	CR10627A (da)
DK (1)	DK2054082T3 (da)
ES (1)	ES2398253T3 (da)
GT (1)	GT200900029A (da)
HK (1)	HK1137339A1 (da)
HR (1)	HRP20130271T1 (da)
IL (1)	IL196612A (da)
MA (1)	MA30667B1 (da)
ME (1)	ME00591A (da)
MX (1)	MX2009000674A (da)
MY (1)	MY150092A (da)
NO (1)	NO341857B1 (da)
NZ (1)	NZ574794A (da)
PL (1)	PL2054082T3 (da)
PT (1)	PT2054082E (da)
RS (1)	RS52685B (da)
RU (1)	RU2429876C2 (da)
SG (1)	SG174033A1 (da)
SI (1)	SI2054082T1 (da)
SV (1)	SV2009003161A (da)
TN (1)	TN2009000036A1 (da)
UA (1)	UA95304C2 (da)
WO (1)	WO2008019144A2 (da)
ZA (1)	ZA200900337B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7750124B2 (en)	2006-09-29	2010-07-06	Oncomed Pharmaceuticals, Inc.	Anti-human DLL4 antibodies and compositions
EP2125013A4 (en) *	2007-01-26	2010-04-07	Bioinvent Int Ab	DLL4 SIGNALING INHIBITOR AND ITS USES
GB0709333D0 (en) *	2007-05-15	2007-06-20	Smart Targeting Ltd	Binding protein
BRPI0913476A2 (pt) *	2008-09-10	2015-12-01	Genentech Inc	"usos de um antagonista tspan12 e usos de um antagonista de norrin"
RU2581962C2 (ru)	2008-09-19	2016-04-20	Медиммун Ллк	Нацеленные средства связывания, направленные на dll4, и их применение
JP5882058B2 (ja)	2008-11-07	2016-03-09	ファブラスエルエルシー	組合せ抗体ライブラリー及びその使用
WO2011008641A1 (en)	2009-07-13	2011-01-20	Beth Israel Deaconess Medical Center, Inc.	Methids of modulating angiogenesis and treatment of angiogenesis-related diseases
MX336152B (es)	2009-08-29	2016-01-08	Abbvie Inc	Proteinas terapeutico de union a dll4.
UY32920A (es) *	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moleculas de unión biespecíficas para la terapia anti-angiogénesis
HUE029661T2 (en)	2009-10-16	2017-03-28	Oncomed Pharm Inc	A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
JO3183B1 (ar)	2010-01-29	2018-03-08	Regeneron Pharma	طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
NZ602734A (en) *	2010-03-02	2014-10-31	Abbvie Inc	Therapeutic dll4 binding proteins
US8551479B2 (en)	2010-09-10	2013-10-08	Oncomed Pharmaceuticals, Inc.	Methods for treating melanoma
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
TWI583699B (zh)	2011-09-23	2017-05-21	安可美德藥物股份有限公司	Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
EP2906295A4 (en) *	2012-10-15	2016-06-01	Oncomed Pharm Inc	METHODS OF TREATING OCULAR DISEASES
WO2014071018A1 (en)	2012-10-31	2014-05-08	Oncomed Pharmaceuticals, Inc.	Methods and monitoring of treatment with a dll4 antagonist
US9931199B2 (en) *	2014-05-05	2018-04-03	Roberto Gustavo ALBERTAZZI	Methods and apparatus for treating keratoconus
WO2016070051A2 (en)	2014-10-31	2016-05-06	Oncomed Pharmaceuticals, Inc.	Combination therapy for treatment of disease
WO2017053705A1 (en)	2015-09-23	2017-03-30	Oncomed Pharmaceuticals, Inc.	Methods and compositions for treatment of cancer
US11679126B2 (en)	2016-11-17	2023-06-20	Chldren's Medical Center Corporation	Methods to enhance microvascular engraftment of bioengineered and primary tissues
EP4417619A1 (en)	2021-10-12	2024-08-21	"Palmira Biopharma" Limited Liability Company	Nucleotide sequence encoding a fusion protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7306799B2 (en) *	1999-06-08	2007-12-11	Regeneron Pharmaceuticals, Inc.	Use of VEGF inhibitors for treatment of eye disorders
US20060134121A1 (en) *	2004-10-29	2006-06-22	Gavin Thurston	DII4 antagonists, assays, and therapeutic methods thereof
CA2621226A1 (en) *	2005-09-01	2007-03-08	Vasgene Therapeutics, Inc.	Methods for using and identifying modulators of delta-like 4
US20080014196A1 (en) *	2006-06-06	2008-01-17	Genentech, Inc.	Compositions and methods for modulating vascular development

2007
- 2007-08-07 PL PL07811137T patent/PL2054082T3/pl unknown
- 2007-08-07 WO PCT/US2007/017546 patent/WO2008019144A2/en active Application Filing
- 2007-08-07 ME MEP-31/09A patent/ME00591A/xx unknown
- 2007-08-07 MY MYPI20090335A patent/MY150092A/en unknown
- 2007-08-07 JP JP2009523820A patent/JP5529536B2/ja active Active
- 2007-08-07 SI SI200731170T patent/SI2054082T1/sl unknown
- 2007-08-07 US US11/890,741 patent/US20080181893A1/en not_active Abandoned
- 2007-08-07 AU AU2007281916A patent/AU2007281916B2/en active Active
- 2007-08-07 UA UAA200902033A patent/UA95304C2/ru unknown
- 2007-08-07 KR KR1020097004668A patent/KR101497355B1/ko active Active
- 2007-08-07 EP EP07811137A patent/EP2054082B1/en active Active
- 2007-08-07 MX MX2009000674A patent/MX2009000674A/es active IP Right Grant
- 2007-08-07 BR BRPI0716424A patent/BRPI0716424B8/pt active IP Right Grant
- 2007-08-07 SG SG2011055829A patent/SG174033A1/en unknown
- 2007-08-07 ES ES07811137T patent/ES2398253T3/es active Active
- 2007-08-07 PT PT78111374T patent/PT2054082E/pt unknown
- 2007-08-07 RS RS20130078A patent/RS52685B/en unknown
- 2007-08-07 DK DK07811137.4T patent/DK2054082T3/da active
- 2007-08-07 NZ NZ574794A patent/NZ574794A/en unknown
- 2007-08-07 RU RU2009107921/15A patent/RU2429876C2/ru active
- 2007-08-07 CA CA2660235A patent/CA2660235C/en active Active
- 2007-08-07 CN CN200780029497.8A patent/CN101500605B/zh active Active
2009
- 2009-01-15 ZA ZA2009/00337A patent/ZA200900337B/en unknown
- 2009-01-20 IL IL196612A patent/IL196612A/en active IP Right Grant
- 2009-02-03 TN TN2009000036A patent/TN2009000036A1/fr unknown
- 2009-02-05 SV SV2009003161A patent/SV2009003161A/es unknown
- 2009-02-06 GT GT200900029A patent/GT200900029A/es unknown
- 2009-02-20 CR CR10627A patent/CR10627A/es unknown
- 2009-02-26 MA MA31667A patent/MA30667B1/fr unknown
- 2009-03-04 NO NO20090984A patent/NO341857B1/no unknown
- 2009-03-05 CO CO09022898A patent/CO6150190A2/es unknown
2010
- 2010-01-29 HK HK10101051.2A patent/HK1137339A1/xx unknown
2013
- 2013-03-25 HR HRP20130271TT patent/HRP20130271T1/hr unknown

Also Published As

Publication number	Publication date
ES2398253T3 (es)	2013-03-14
NO341857B1 (no)	2018-02-12
BRPI0716424B8 (pt)	2021-05-25
UA95304C2 (ru)	2011-07-25
PT2054082E (pt)	2013-03-07
RS52685B (en)	2013-08-30
ME00591B (me)	2011-12-20
GT200900029A (es)	2009-11-17
SV2009003161A (es)	2010-02-01
CA2660235A1 (en)	2008-02-14
NZ574794A (en)	2011-06-30
BRPI0716424B1 (pt)	2018-06-26
AU2007281916A1 (en)	2008-02-14
RU2009107921A (ru)	2010-09-20
JP2010500355A (ja)	2010-01-07
HRP20130271T1 (hr)	2013-04-30
ZA200900337B (en)	2009-12-30
IL196612A0 (en)	2011-08-01
CN101500605B (zh)	2014-04-30
MA30667B1 (fr)	2009-08-03
US20080181893A1 (en)	2008-07-31
SI2054082T1 (sl)	2013-04-30
SG174033A1 (en)	2011-09-29
CO6150190A2 (es)	2010-04-20
KR20090039823A (ko)	2009-04-22
HK1137339A1 (en)	2010-07-30
EP2054082A2 (en)	2009-05-06
CN101500605A (zh)	2009-08-05
IL196612A (en)	2012-02-29
RU2429876C2 (ru)	2011-09-27
EP2054082B1 (en)	2012-12-26
JP5529536B2 (ja)	2014-06-25
AU2007281916B2 (en)	2012-06-28
WO2008019144A3 (en)	2008-03-27
MX2009000674A (es)	2009-02-04
ME00591A (en)	2011-12-20
NO20090984L (no)	2009-03-04
WO2008019144A2 (en)	2008-02-14
TN2009000036A1 (en)	2010-08-19
BRPI0716424A2 (pt)	2014-05-20
CA2660235C (en)	2015-09-22
MY150092A (en)	2013-11-29
CR10627A (es)	2009-04-14
PL2054082T3 (pl)	2013-05-31
KR101497355B1 (ko)	2015-03-02

Publication	Publication Date	Title
DK2054082T3 (da)	2013-01-21	Anvendelse af D114-antagonister til behandling af iskæmiske skader eller vaskulær insufficiens
HK1255283A1 (zh)	2019-08-09	用於治療流感的化合物和方法
NL300938I2 (nl)	2019-01-08	Niraparib tosylaat of niraparib tosylaat monohydraat
DK2448637T3 (da)	2014-05-26	Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
DK2498771T3 (da)	2014-01-27	Anvendelse af bethanechol til behandling af xerostomi
DK2350096T3 (da)	2020-03-02	Fremgangsmåder til behandling af hepatisk encephalopati
DK2451796T3 (da)	2013-07-29	Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK2449057T3 (da)	2021-11-08	Fremgangsmåde til omdannelse af lignocellulosematerialer til anvendelige kemikalier
DK2271642T3 (da)	2014-04-22	Pyridylinhibitorer af hedgehog signalering
DK2349310T3 (da)	2014-08-11	Polypeptid til behandling eller forebyggelse af adhæsioner
BR112012021374A2 (pt)	2016-10-25	" plataforma de pernas atirantadas "
EP2419392A4 (en)	2013-02-27	perfluorocarbon emulsions
DK2293816T3 (da)	2013-02-04	Fremgangsmåder til behandling af reumatoid arthritis
EP2361224A4 (en)	2013-03-06	USE OF REALIZATION WASTE
DK2451482T3 (da)	2019-07-22	Kombinationsterapi til behandlingen af diabetes
DK2382232T3 (da)	2013-12-16	Fremgangsmåde til fremstilling af bivalirudin
DK2411009T3 (da)	2013-06-24	Terapeutiske anvendelser af quinazolindionderivater
DK2453858T3 (da)	2014-11-03	Fremgangsmåde
DK2435583T3 (da)	2014-09-29	miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI
DK1855711T3 (da)	2009-10-12	Anvendelse af BAFF til behandling af Th2-medierede tilstande
EP2507309A4 (en)	2013-07-03	NETWORKING RESOURCES
DK2334186T3 (da)	2013-04-08	Anvendelse af e-vitamin eller estere heraf til bekæmpelse af ektoparasitter
DK2162238T3 (da)	2014-05-26	Overfladebehandling af termisk modificeret træ
DK2501381T3 (da)	2017-11-06	Behandling af atrieflimmer
DK2285416T3 (da)	2012-09-10	Konjugat til behandlingen af mesotheliom